Clinical Research Directory
Browse clinical research sites, groups, and studies.
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Sponsor: Neurocrine Biosciences
Summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Official title: A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
284
Start Date
2025-08-11
Completion Date
2027-11
Last Updated
2026-05-15
Healthy Volunteers
No
Conditions
Interventions
NBI-1117568
NBI-1117568 will be administered per schedule specified in the arm description.
Placebo
Placebo will be administered per schedule specified in the arm description.
Locations (15)
Neurocrine Clinical Site
Culver City, California, United States
Neurocrine Clinical Site
Garden Grove, California, United States
Neurocrine Clinical Site
Riverside, California, United States
Neurocrine Clinical Site
Atlanta, Georgia, United States
Neurocrine Clinical Site
North Canton, Ohio, United States
Neurocrine Clinical Site
Sliven, Bulgaria
Neurocrine Clinical Site
Veliko Tarnovo, Bulgaria
Neurocrine Clinical Site
Vratsa, Bulgaria
Neurocrine Clinical Site
Győr, Hungary
Neurocrine Clinical Site
Brasov, Romania
Neurocrine Clinical Site
Brasov, Romania
Neurocrine Clinical Site
Bucharest, Romania
Neurocrine Clinical Site
Belgrade, Serbia
Neurocrine Clinical Site
Gornja Toponica, Serbia
Neurocrine Clinical Site
Kragujevac, Serbia